Universitat Autònoma de Barcelona (UAB), Medical School, Upper Gastrointestinal and Bariatric Surgery Unit, Department of General and Digestive Surgery, Hospital de la Santa Creu i Sant Pau, Sant Quintí 89, 08041, Barcelona, Spain.
Surgery Research, Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain.
Surg Endosc. 2024 Nov;38(11):6332-6337. doi: 10.1007/s00464-024-11071-8. Epub 2024 Aug 29.
Splenectomy has been used as a diagnostic and therapeutic tool in the management of hematological diseases for many years. However, the emergence of new medical therapies has modified guidelines for many hematological diseases for which splenectomy was previously considered. We aimed to evaluate the evidence of a decrease in the hematological indications for splenectomy and the reasons and justifications for this change.
We conducted a single-center, retrospective analysis of patients who underwent laparoscopic splenectomy for hematological disease between January 2010 and December 2023. Patients were classified into four groups: 1 autoimmune and hemolytic diseases (HAD), (2) lymphomas, (3) myeloproliferative diseases (MPN), and (4) other splenic diseases. We recorded the annual incidence of splenectomy and the ratio of new medical cases, demographic and clinical data and surgical outcomes.
During the study period, 98 patients were referred for splenectomy. There was a significant progressive decrease in this surgical indication, particularly regarding HAD (p < 0.001). The indication for splenectomy for immune thrombocytopenic purpura (ITP) declined to zero despite an increase in the number of patients diagnosed with this disorder (p < 0.001). The pattern of decrease in AHAI and Evans syndrome was similar to that in ITP. The group of splenectomies due to lymphoma persisted consistently during the study period, as did the indication for splenectomy in the context of lymphoma treatment. Splenectomy due to massive splenomegaly secondary to MPN was indicated only in one patient. Splenectomies due to other causes were similarly distributed over the years.
Our findings confirm a significant decrease in the indication for elective surgery for hematological diseases, mainly regarding autoimmune disease. The surgical community and surgical departments should be aware of this situation yet maintain the skills to adopt this technique both safely and efficiently.
脾切除术多年来一直被用作治疗血液病的诊断和治疗工具。然而,新的医学治疗方法的出现已经改变了许多以前认为需要脾切除术的血液病的指南。我们旨在评估脾切除术的血液学适应证减少的证据,以及这种变化的原因和依据。
我们对 2010 年 1 月至 2023 年 12 月期间因血液病行腹腔镜脾切除术的患者进行了单中心回顾性分析。患者分为四组:1. 自身免疫性和溶血性疾病(HAD);2. 淋巴瘤;3. 骨髓增生性疾病(MPN);4. 其他脾脏疾病。我们记录了脾切除术的年发生率和新的医学病例比例、人口统计学和临床数据以及手术结果。
在研究期间,有 98 例患者因脾切除术而转诊。脾切除术的这种手术指征明显减少,特别是针对 HAD(p<0.001)。尽管诊断出患有这种疾病的患者数量有所增加,但特发性血小板减少性紫癜(ITP)的脾切除术指征已降至零(p<0.001)。AHAI 和 Evans 综合征的减少模式与 ITP 相似。淋巴瘤组的脾切除术在研究期间一直保持不变,淋巴瘤治疗中的脾切除术指征也是如此。由于 MPN 导致的巨大脾肿大而进行的脾切除术仅在一名患者中进行。由于其他原因进行的脾切除术在这些年中分布均匀。
我们的发现证实了血液系统疾病的择期手术适应证显著减少,主要涉及自身免疫性疾病。外科医生和外科部门应该意识到这种情况,但仍要保持安全有效地采用这种技术的技能。